
Quest Diagnostics Incorporated (NYSE:DGX – Free Report) – Analysts at Zacks Research cut their Q1 2027 EPS estimates for shares of Quest Diagnostics in a research report issued on Thursday, November 12th. Zacks Research analyst Team now expects that the medical research company will post earnings of $2.61 per share for the quarter, down from their prior forecast of $2.72. The consensus estimate for Quest Diagnostics’ current full-year earnings is $11.29 per share. Zacks Research also issued estimates for Quest Diagnostics’ Q3 2027 earnings at $3.08 EPS, FY2027 earnings at $11.69 EPS, Q1 2028 earnings at $2.97 EPS, Q2 2028 earnings at $3.24 EPS and FY2028 earnings at $12.77 EPS.
Quest Diagnostics (NYSE:DGX – Get Free Report) last released its quarterly earnings results on Thursday, October 22nd. The medical research company reported $3.00 EPS for the quarter, beating the consensus estimate of $2.87 by $0.13. The firm had revenue of $3.10 billion during the quarter, compared to the consensus estimate of $3.05 billion. Quest Diagnostics had a net margin of 9.53% and a return on equity of 16.21%. Quest Diagnostics’s revenue for the quarter was up 10.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.60 EPS.
DGX has been the topic of a number of other research reports. Wall Street Zen raised Quest Diagnostics from a “hold” rating to a “buy” rating in a report on Tuesday, July 28th. Argus set a $260.00 price target on Quest Diagnostics in a research report on Wednesday, July 29th. Mizuho upped their price objective on Quest Diagnostics from $235.00 to $260.00 and gave the company an “outperform” rating in a research note on Friday, July 24th. Weiss Ratings raised Quest Diagnostics from a “buy (a)” rating to a “buy (a+)” rating in a research report on Wednesday, October 21st. Finally, Robert W. Baird set a $262.00 price objective on Quest Diagnostics in a research report on Friday, October 23rd. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $248.70.
Check Out Our Latest Research Report on Quest Diagnostics
Quest Diagnostics Price Performance
Shares of NYSE:DGX opened at $261.67 on Monday. The company has a 50-day simple moving average of $241.72 and a 200-day simple moving average of $215.98. Quest Diagnostics has a one year low of $171.18 and a one year high of $263.19. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.58 and a current ratio of 1.70. The stock has a market capitalization of $28.79 billion, a price-to-earnings ratio of 23.52, a PEG ratio of 2.32 and a beta of 0.55.
Quest Diagnostics Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 27th. Shareholders of record on Tuesday, January 12th will be paid a $0.86 dividend. This represents a $3.44 annualized dividend and a yield of 1.3%. The ex-dividend date of this dividend is Tuesday, January 12th. Quest Diagnostics’s payout ratio is currently 34.26%.
Insider Buying and Selling
In other news, EVP Catherine T. Doherty sold 22,105 shares of the firm’s stock in a transaction on Tuesday, November 3rd. The shares were sold at an average price of $248.02, for a total value of $5,482,482.10. Following the completion of the sale, the executive vice president owned 71,949 shares in the company, valued at approximately $17,844,790.98. This trade represents a 23.50% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Patrick Plewman sold 11,717 shares of the firm’s stock in a transaction on Monday, November 9th. The stock was sold at an average price of $257.34, for a total transaction of $3,015,252.78. Following the completion of the sale, the senior vice president owned 14,684 shares of the company’s stock, valued at $3,778,780.56. This trade represents a 44.38% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 79,478 shares of company stock worth $19,794,031 in the last ninety days. Insiders own 0.88% of the company’s stock.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently made changes to their positions in the company. BlackRock Inc. acquired a new stake in Quest Diagnostics in the second quarter valued at about $1,965,923,000. EdgePoint Investment Group Inc. increased its position in Quest Diagnostics by 35.1% during the 1st quarter. EdgePoint Investment Group Inc. now owns 2,243,869 shares of the medical research company’s stock worth $439,753,000 after purchasing an additional 582,797 shares during the period. Bank of America Corp DE acquired a new position in Quest Diagnostics during the 2nd quarter worth approximately $410,151,000. Dimensional Fund Advisors LP raised its stake in shares of Quest Diagnostics by 0.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,949,535 shares of the medical research company’s stock worth $382,085,000 after buying an additional 17,987 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its stake in shares of Quest Diagnostics by 28.0% during the 3rd quarter. Goldman Sachs Group Inc. now owns 1,257,894 shares of the medical research company’s stock worth $293,177,000 after buying an additional 275,200 shares in the last quarter. 88.06% of the stock is currently owned by institutional investors and hedge funds.
Top Quest Diagnostics Stories
These are some of the DGX stories that stood out recently:
- Positive Sentiment: Recent quarterly results provided support: Quest reported EPS of $3.00 and revenue of $3.10 billion, both above estimates, with revenue up 10% year over year.
- Neutral Sentiment: Chief Accounting Officer Michael Deppe sold 11,776 shares for about $3.06 million, reducing his holding by 25.07%. The trade was made under a pre-arranged Rule 10b5-1 plan, which makes it less indicative of a sudden change in outlook. SEC filing
- Negative Sentiment: Zacks Research lowered several future EPS forecasts, including Q1 2027 to $2.61 from $2.72, FY2027 to $11.69 from $11.73, and FY2028 to $12.77 from $12.90. The reductions are small but suggest slightly softer expectations for earnings growth. Q1 EPS estimates cut
About Quest Diagnostics
Quest Diagnostics (NYSE: DGX) is a provider of diagnostic information services, conducting laboratory tests that help physicians and other health care professionals diagnose, monitor and manage medical conditions. Its services include routine blood and other clinical laboratory testing, anatomic pathology, and specialized molecular and genetic testing. The company serves patients, physicians, hospitals, health plans, employers and government organizations. In addition to testing performed through its laboratories and patient service centers, Quest offers services such as workplace drug testing and diagnostic support for clinical research.
Recommended Stories
- Five stocks we like better than Quest Diagnostics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
